When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
Part 1 – Case Presentation Brian A. Jonas, MD, PhD, FACP, presents the case of patient “J.S.” to fellow faculty members Daniel A. Pollyea, MD, MS, and Gabriel…
Part 2 – Case Discussion Brian A. Jonas, MD, PhD, FACP, presents the case of patient “J.S.” to fellow faculty members Daniel A. Pollyea, MD, MS, and Gabriel…
Part 3 – Case Discussion & Wrap-up Brian A. Jonas, MD, PhD, FACP, presents the case of patient “J.S.” to fellow faculty members Daniel A. Pollyea, MD, MS,…
